Chemotherapy and resection for gastric cancer with synchronous liver metastases

被引:38
作者
Chen, Lei [1 ,2 ]
Song, Ming-Quan [3 ]
Lin, Hui-Zhong [1 ]
Hao, Lin-Hua [4 ]
Jiang, Xiang-Jun [3 ]
Li, Zi-Yu [5 ]
Chen, Yu-Xin [6 ]
机构
[1] Qingdao Municipal Hosp, Dept Surg, Qingdao 266011, Shandong, Peoples R China
[2] Shandong Univ, Sch Med, Jinan 250012, Shandong, Peoples R China
[3] Qingdao Municipal Hosp, Dept Gastroenterol, Qingdao 266011, Shandong, Peoples R China
[4] State Ocean Adm, Inst Oceanog 1, Qingdao 266011, Shandong, Peoples R China
[5] Peking Univ, Key Lab Carcinogenesis & Translat Res, Beijing Canc Hosp & Inst, Dept Surg,Minist Educ,Sch Oncol, Beijing 100142, Peoples R China
[6] Shandong Univ, Sch Med, Qilu Hosp, Dept Surg, Jinan 250012, Shandong, Peoples R China
关键词
Gastric cancer; Liver metastases; Surgery; Chemotherapy; Pilot study; PHASE-I TRIAL; 1ST-LINE TREATMENT; INDUCTION CHEMOTHERAPY; SURGICAL RESECTION; MODIFIED DOCETAXEL; CISPLATIN; 5-FLUOROURACIL; RADIOTHERAPY; CARCINOMA; SURGERY;
D O I
10.3748/wjg.v19.i13.2097
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the effect of surgery and chemotherapy for gastric cancer with multiple synchronous liver metastases (GCLM). METHODS: A total of 114 patients were entered in this study, and 20 patients with multiple synchronous liver metastases were eligible. After screening with preoperative chemotherapy, 20 patients underwent curative gastrectomy and hepatectomy for GCLM; 14 underwent major hepatectomy, and the remaining six underwent minor hepatectomy. There were 94 patients without aggressive treatment, and they were in the non-operative group. Two regimens of perioperative chemotherapy were used: S-1 and cisplatin (SP) in 12 patients, and docetaxel, cisplatin and 5-fluorouracil (DCF) in eight patients. These GCLM patients were given preoperative chemotherapy consisting of two courses chemotherapy of SP or DCF regimens. After chemotherapy, gastrectomy and hepatectomy were preformed. Evaluation of patient survival was by follow-up contact using telephone and outpatient records. All patients were assessed every 3 mo during the first year and every 6 mo thereafter. RESULTS: Twenty patients underwent gastrectomy and hepatectomy and completed their perioperative chemotherapy and hepatic arterial infusion before and after surgery. Ninety-four patients had no aggressive treatment of liver metastases because of technical difficulties with resection and severe cardiopulmonary dysfunction. In the surgery group, there was no toxicity greater than grade 3 during the course of chemotherapy. The response rate was 100% according to the Response Evaluation Criteria in Solid Tumors Criteria. For all 114 patients, the overall survival rate was 8.0%, 4.0%, 4.0% and 4.0% at 1, 2, 3 and 4 years, respectively, with a median survival time (MST) of 8.5 mo (range: 0.5-48 mo). For the 20 patients in the surgery group, MST was 22.3 mo (range: 4-48 mo). In the 94 patients without aggressive treatment, MST was 5.5 mo (range: 0.5-21 mo). There was a significant difference between the surgery and unresectable patients (P = 0.000). Three patients in surgery group were still alive at the end of the cut-off date. CONCLUSION: Perioperative weekly DCF and SP achieved a good response, and combined with surgery, they could improve prognosis of GCLM. (C) 2013 Baishideng. All rights reserved.
引用
收藏
页码:2097 / 2103
页数:7
相关论文
共 31 条
[1]   A phase II study of modified FOLFOX as first-line chemotherapy for metastatic gastric cancer in elderly patients with associated diseases [J].
Catalano, Vincenzo ;
Bisonni, Renato ;
Graziano, Francesco ;
Giordani, Paolo ;
Alessandroni, Paolo ;
Baldelli, Anna Maria ;
Casadei, Virginia ;
Rossi, David ;
Fedeli, Stefano Luzi ;
D'Emidio, Silvia ;
Giustini, Lucio ;
Fiorentini, Giammaria .
GASTRIC CANCER, 2013, 16 (03) :411-419
[2]   Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J].
Cunningham, David ;
Allum, William H. ;
Stenning, Sally P. ;
Thompson, Jeremy N. ;
Van de Velde, Cornelis J. H. ;
Nicolson, Marianne ;
Scarffe, J. Howard ;
Lofts, Fiona J. ;
Falk, Stephen J. ;
Iveson, Timothy J. ;
Smith, David B. ;
Langley, Ruth E. ;
Verma, Monica ;
Weeden, Simon ;
Chua, Yu Jo .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (01) :11-20
[3]   Resection of liver metastases is beneficial in patients with gastric cancer: report on 15 cases and review of literature [J].
Dittmar, Yves ;
Altendorf-Hofmann, Annelore ;
Rauchfuss, Falk ;
Goetz, Max ;
Scheuerlein, Hubert ;
Jandt, Karin ;
Settmacher, Utz .
GASTRIC CANCER, 2012, 15 (02) :131-136
[4]  
Fujii K, 2001, HEPATO-GASTROENTEROL, V48, P368
[5]   A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501) [J].
Higuchi, Katsuhiko ;
Koizumi, Wasaburo ;
Tanabe, Satoshi ;
Sasaki, Tohru ;
Katada, Chikatoshi ;
Ishiyama, Hiromichi ;
Hayakawa, Kazushige .
RADIOTHERAPY AND ONCOLOGY, 2008, 87 (03) :398-404
[6]   Docetaxel and Cisplatin Plus Fluorouracil Compared With Modified Docetaxel, Cisplatin, and 5-Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Retrospective Analysis of Single Institution [J].
Inal, A. ;
Kaplan, M. A. ;
Kucukoner, M. ;
Isikdogan, A. .
NEOPLASMA, 2012, 59 (02) :233-236
[7]   Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer [J].
Jeong, Jae-Heon ;
Lim, Sun Min ;
Yun, Ji Young ;
Rhee, Gwang Won ;
Lim, Jae Yun ;
Cho, Jae Yong ;
Kim, Yu Ri .
ONCOLOGY, 2012, 83 (05) :292-299
[8]  
KAJITANI T, 1981, JPN J SURG, V11, P127
[9]   Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck [J].
Keil, Felix ;
Selzer, Edgar ;
Berghold, Andrea ;
Reinisch, Sabine ;
Kapp, Karin S. ;
De Vries, Alexander ;
Greil, Richard ;
Bachtiary, Barbara ;
Tinchon, Christoph ;
Anderhuber, Wolfgang ;
Burian, Martin ;
Kasparek, Anne-Katrin ;
Elsaesser, Wolfgang ;
Kainz, Herbert ;
Riedl, Regina ;
Kopp, Michael ;
Kornek, Gabriela .
EUROPEAN JOURNAL OF CANCER, 2013, 49 (02) :352-359
[10]  
Keskin S, 2012, CLIN TRANSL ONCOL, DOI [10.1007/s120-012-1942-8, DOI 10.1007/S120-012-1942-8]